362 related articles for article (PubMed ID: 28116950)
1. A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).
Shafiq I; Bulman ZP; Spitznogle SL; Osorio JE; Reilly IS; Lesse AJ; Parameswaran GI; Mergenhagen KA; Tsuji BT
Infect Dis (Lond); 2017 May; 49(5):410-416. PubMed ID: 28116950
[TBL] [Abstract][Full Text] [Related]
2. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
Werth BJ; Barber KE; Ireland CE; Rybak MJ
Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
[TBL] [Abstract][Full Text] [Related]
4. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
Werth BJ; Sakoulas G; Rose WE; Pogliano J; Tewhey R; Rybak MJ
Antimicrob Agents Chemother; 2013 Jan; 57(1):66-73. PubMed ID: 23070161
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
Steed M; Vidaillac C; Rybak MJ
Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
[TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.
Barber KE; Rybak MJ; Sakoulas G
J Antimicrob Chemother; 2015 Jan; 70(1):311-3. PubMed ID: 25125677
[No Abstract] [Full Text] [Related]
8. Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of
Kebriaei R; Rice SA; Stamper KC; Rybak MJ
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670436
[TBL] [Abstract][Full Text] [Related]
9. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: An Update on New Therapeutic Approaches.
Holubar M; Meng L; Alegria W; Deresinski S
Infect Dis Clin North Am; 2020 Dec; 34(4):849-861. PubMed ID: 33011050
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates.
Vidaillac C; Leonard SN; Rybak MJ
Int J Antimicrob Agents; 2010 Jun; 35(6):527-30. PubMed ID: 20346632
[TBL] [Abstract][Full Text] [Related]
11. Bacteremia due to Methicillin-Resistant Staphylococcus aureus: New Therapeutic Approaches.
Holubar M; Meng L; Deresinski S
Infect Dis Clin North Am; 2016 Jun; 30(2):491-507. PubMed ID: 27208769
[TBL] [Abstract][Full Text] [Related]
12. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.
Rose WE; Schulz LT; Andes D; Striker R; Berti AD; Hutson PR; Shukla SK
Antimicrob Agents Chemother; 2012 Oct; 56(10):5296-302. PubMed ID: 22869564
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
[TBL] [Abstract][Full Text] [Related]
14. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Sader HS; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
[TBL] [Abstract][Full Text] [Related]
17. The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.
Barber KE; Werth BJ; Rybak MJ
J Antimicrob Chemother; 2015 Feb; 70(2):505-9. PubMed ID: 25246437
[TBL] [Abstract][Full Text] [Related]
18. In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin.
Vidaillac C; Parra-Ruiz J; Rybak MJ
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):470-3. PubMed ID: 22018937
[TBL] [Abstract][Full Text] [Related]
19. Rates of killing of methicillin-resistant Staphylococcus aureus by ceftaroline, daptomycin, and telavancin compared to that of vancomycin.
Marconescu P; Graviss EA; Musher DM
Scand J Infect Dis; 2012 Aug; 44(8):620-2. PubMed ID: 22668202
[TBL] [Abstract][Full Text] [Related]
20. Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia.
Espedido BA; Jensen SO; van Hal SJ
J Antimicrob Chemother; 2015 Mar; 70(3):797-801. PubMed ID: 25406295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]